rese-cel (resecabtagene autoleucel)
Systemic Lupus Erythematosus (SLE)
Key Facts
About Cabaletta Bio
Cabaletta Bio is focused on developing engineered T cell therapies to potentially cure patients with autoimmune diseases by resetting the immune system. The company leverages its proprietary Cabaletta Approach to B cell Ablation (CABA) platform, which includes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach. Its lead candidate, rese-cel, is being evaluated in five RESET Phase 1/2 trials across rheumatology, dermatology, and neurology indications. Cabaletta aims to build a leading, fully integrated cell therapy company focused on transforming the treatment paradigm for autoimmune diseases.
View full company profileAbout Cabaletta Bio
Cabaletta Bio is focused on developing engineered T cell therapies to potentially cure patients with autoimmune diseases by resetting the immune system. The company leverages its proprietary Cabaletta Approach to B cell Ablation (CABA) platform, which includes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach. Its lead candidate, rese-cel, is being evaluated in five RESET Phase 1/2 trials across rheumatology, dermatology, and neurology indications. Cabaletta aims to build a leading, fully integrated cell therapy company focused on transforming the treatment paradigm for autoimmune diseases.
View full company profileAbout Cabaletta Bio
Cabaletta Bio is focused on developing engineered T cell therapies to potentially cure patients with autoimmune diseases by resetting the immune system. The company leverages its proprietary Cabaletta Approach to B cell Ablation (CABA) platform, which includes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach. Its lead candidate, rese-cel, is being evaluated in five RESET Phase 1/2 trials across rheumatology, dermatology, and neurology indications. Cabaletta aims to build a leading, fully integrated cell therapy company focused on transforming the treatment paradigm for autoimmune diseases.
View full company profileAbout Cabaletta Bio
Cabaletta Bio is focused on developing engineered T cell therapies to potentially cure patients with autoimmune diseases by resetting the immune system. The company leverages its proprietary Cabaletta Approach to B cell Ablation (CABA) platform, which includes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach. Its lead candidate, rese-cel, is being evaluated in five RESET Phase 1/2 trials across rheumatology, dermatology, and neurology indications. Cabaletta aims to build a leading, fully integrated cell therapy company focused on transforming the treatment paradigm for autoimmune diseases.
View full company profileAbout Cabaletta Bio
Cabaletta Bio is focused on developing engineered T cell therapies to potentially cure patients with autoimmune diseases by resetting the immune system. The company leverages its proprietary Cabaletta Approach to B cell Ablation (CABA) platform, which includes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach. Its lead candidate, rese-cel, is being evaluated in five RESET Phase 1/2 trials across rheumatology, dermatology, and neurology indications. Cabaletta aims to build a leading, fully integrated cell therapy company focused on transforming the treatment paradigm for autoimmune diseases.
View full company profileAbout Cabaletta Bio
Cabaletta Bio is focused on developing engineered T cell therapies to potentially cure patients with autoimmune diseases by resetting the immune system. The company leverages its proprietary Cabaletta Approach to B cell Ablation (CABA) platform, which includes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach. Its lead candidate, rese-cel, is being evaluated in five RESET Phase 1/2 trials across rheumatology, dermatology, and neurology indications. Cabaletta aims to build a leading, fully integrated cell therapy company focused on transforming the treatment paradigm for autoimmune diseases.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| Cenerimod | Idorsia | Phase 3 |
| CLN-978 | Cullinan Therapeutics | Phase 1 |
| Telitacicept | Vor Biopharma | Marketed |
| Dapirolizumab Pegol | Silence Therapeutics | Phase 3 |